Flux in Indian foreign investment regulations delays some pharma deals
This article was originally published in Scrip
Executive Summary
India's regulatory mechanism for vetting brown field foreign direct investment (FDI) proposals appears to be in a state of flux. A group of ministers is expected to examine whether the current interim arrangement whereby such proposals are considered by India's Foreign Investment Promotion Board (FIPB) should be extended, and how the competition law might be amended to expand its coverage to include generally smaller threshold pharma deals.